Brain-Wide Quantification of Blood-Brain Barrier Penetrating Antibody Therapeutics
openNIA - National Institute on Aging
The process of delivering antibody-based therapeutics drugs to the brain is complicated by the need to penetrate
the blood-brain barrier (BBB), prompting interest in BBB-penetrating strategies for antibody therapeutics.
However, the methods to test brain penetration of these drugs are inadequate due to the intermingling of blood
vessels and brain tissue, which confounds the signal of drug penetration. Current methods for measuring the
distribution of antibody drugs in the brain are inadequate, lacking in accuracy, reliability and the capacity for
three-dimensional, high-resolution, quantitative analysis. Addressing this technological shortfall, Translucence
Biosystems is enhancing its proprietary 3D brain imaging and analysis platform to create a specialized
Vasculature Subtraction Parenchymal Quantification (VSPQ) workflow. This tool aims to isolate and measure
only the therapeutically relevant antibody drug within the brain parenchyma. The Phase II goal is to refine this
approach to ensure precise measurement, leveraging the company’s experience and expertise in neuroscience,
artificial intelligence (AI), and technology commercialization. The specific aims of the project are to develop and
qualify the VSPQ workflow using machine learning algorithms to distinguish between vasculature and
parenchyma signals, targeting 95% sensitivity and specificity relative to human assessments; integrate the
VSPQ workflow into the existing 3D imaging platform, ensuring that the AI-generated data correlates strongly
with manually partitioned regional data; validate the utility of the software through blind analysis of data provided
by strategic partners, demonstrating its robustness and accuracy in real-world conditions; and validate a cloud-
based version of the pipeline, ensuring that it is stable, reliable, and performs consistently with the local version.
The impact of this research is poised to be significant, providing a vital tool for Alzheimer's disease drug discovery
and potentially improving the rate of successful treatment development. By offering the VSPQ workflow as a
cloud-based software-as-a-service, Translucence Biosystems is aiming to make this innovative technology
widely accessible, thereby streamlining the drug development pipeline and bringing new therapies to patients
more efficiently.
Up to $1.4M
health research